Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Joerg Moeller

Bayer symbol

Bayer boosts consumer care business with Steigerwald purchase

Fuels ambition to become world leader in OTC medicines

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

Shire misses Q1 targets as Replagal sales fall

Reduces 2013 revenue forecasts

Bayer symbol

Bayer expands birth control business with $1.1bn Conceptus acquisition

Adds permanent contraception Essure to portfolio

Bayer symbol

Bayer’s riociguat fast-tracked by FDA

Could provide oral option in pulmonary arterial hypertension market

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

- PMLiVE

Bayer sues Glenmark over its skin disorder generic

India-based firm files for US approval of its version of Finacea

Shire acquires Swiss biotech Premacure

Gains phase II eye drug for rare infant condition

Bupa swipes Shire’s SVP of global commercial operations

Theresa Heggie joins as chief strategy and marketing officer

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links